<DOC>
	<DOCNO>NCT02541643</DOCNO>
	<brief_summary>To provide elotuzumab treatment single-patient use .</brief_summary>
	<brief_title>Expanded Access Single Named Patient Program With Elotuzumab ( BMS-901608 ) Treatment Patient R-A With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Signed Written Informed Consent ) Before program procedure perform , patient detail program describe , give write informed consent document read . Then , patient consent participate program , indicate consent signing date informed consent document presence program personnel . Other Criteria ) Patients must willing refrain blood donation program drug therapy 8 week therapy . Age Reproductive Status 1 . Men woman , age 18 year 2 . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start study drug . 3 . Women must breastfeed 4 . WOCBP must use method ( ) contraception indicate Informed Consent Form . Because teratogenic potential elotuzumab , highly effective method ( ) contraception ( failure rate le 1 % per year ) require . The individual method contraception duration determine consultation investigator . In study men WOCBP must use method contraception least 1 month ( 4 week ) woman 8 week , men 90 day , last dose elotuzumab . 5 . Males sexually active WOCBP must use contraceptive method failure rate le 1 % per year . The investigator shall review contraception method time period contraception must follow . Men sexually active WOCB must agree follow instruction method ( ) contraception duration treatment elotuzumab plus 5 halflives program drug plus 90 day ( duration sperm turnover ) total 90 day posttreatment completion . 6 . Women childbearing potential ( ie , postmenopausal surgically sterile azoospermic men require contraception . Sex Reproductive Status 1 . WOCBP use 2 form effective birth control . 2 . Women positive pregnancy test enrollment prior administration program medication . Other Exclusion Criteria 1 . Prisoners patient involuntarily incarcerate . 2 . Patients compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness . Elotuzumab CA204022 BMS901608 Expanded Access Guidance Document 23 Eligibility criterion program carefully consider ensure safety program patient ensure result program use . It imperative patient fully meet eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Relapsed/Refractory Multiple Myeloma</keyword>
</DOC>